Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW8Z1M
|
|||
| Drug Name |
RIST4721
|
|||
| Synonyms |
vimnerixin; AZD4721; RIST4721; AZD-4721; RIST-4721; X09ORN2BF0; 1418112-77-2; UNII-X09ORN2BF0; AZD-4721 [WHO-DD]; 1-Azetidinesulfonamide, N-(6-((1R,2S)-2,3-dihydroxy-1-methylpropoxy)-2-(((4-fluorophenyl)methyl)thio)-4-pyrimidinyl)-3-methyl-; vimnerixin [INN]; Azd 4721; CHEMBL5095217; SCHEMBL14579049; GTPL12100; AZD 4721 [WHO-DD]; AZD4721;RIST4721; AKOS040756752; compound 4 [WO2019055509A1]; MS-28748; HY-145640; CS-0377236; F83913; N-(6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}-2-{[(4-fluorophenyl)methyl]sulfanyl}pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide; N-[6-[(1R,2S)-2,3-Dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl-1-azetidinesulfonamide; N-[6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Hidradenitis suppurativa [ICD-11: ED92.0; ICD-10: L73.2] | Phase 2 | [1] | |
| Palmoplantar pustulosis [ICD-11: EA90.42; ICD-10: L40.3] | Phase 2 | [2] | ||
| Company |
Pfzer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H25FN4O5S2
|
|||
| Canonical SMILES |
CC1CN(C1)S(=O)(=O)NC2=CC(=NC(=N2)SCC3=CC=C(C=C3)F)OC(C)C(CO)O
|
|||
| InChI |
InChI=1S/C19H25FN4O5S2/c1-12-8-24(9-12)31(27,28)23-17-7-18(29-13(2)16(26)10-25)22-19(21-17)30-11-14-3-5-15(20)6-4-14/h3-7,12-13,16,25-26H,8-11H2,1-2H3,(H,21,22,23)/t13-,16+/m1/s1
|
|||
| InChIKey |
UCCNQCNIPRKLRP-CJNGLKHVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Antagonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Endocytosis | ||||
| Epithelial cell signaling in Helicobacter pylori infection | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05348681) A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05194839) A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis. U.S.National Institutes of Health. | |||
| REF 3 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.